Mesenchymal stem cells as therapeutics and vehicles for gene and drug delivery

Advanced Drug Delivery Reviews

Volumn 62, Issue 12, 2010, Pages 1156-1166

  Porada, Christopher D ^a   Almeida Porada, Graça ^a  

^a UNIVERSITY OF NEVADA   (United States)

Author keywords

Cellular reprogramming; Delivery vehicle; Immunomodulation; Stroma; Trophic factor

Indexed keywords

CELLULAR REPROGRAMMING; DELIVERY VEHICLE; IMMUNOMODULATION; STROMA; TROPHIC FACTOR;

DRUG DELIVERY; GENE THERAPY; STEM CELLS; VEHICLES;

CELL CULTURE;

BASIC FIBROBLAST GROWTH FACTOR; BLOOD CLOTTING FACTOR 8; SCATTER FACTOR; SOMATOMEDIN B; SOMATOMEDIN C; VASCULOTROPIN; VIRUS VECTOR;

ANTIINFLAMMATORY ACTIVITY; BONE MARROW CELL; CANCER GENE THERAPY; CELL DIFFERENTIATION; CELL ISOLATION; DRUG DELIVERY SYSTEM; GENE DELIVERY SYSTEM; GLIOBLASTOMA; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIVER DISEASE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; NONHUMAN; PRIORITY JOURNAL; REGENERATIVE MEDICINE; REVIEW; STEM CELL GENE THERAPY;

CELL DIFFERENTIATION; CELL PROLIFERATION; DRUG DELIVERY SYSTEMS; GENE THERAPY; GENETIC VECTORS; HUMANS; IMMUNE TOLERANCE; IMMUNOMODULATION; IMMUNOSUPPRESSION; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; NEOPLASMS; TISSUE ENGINEERING;

EID: 78650178107     PISSN: 0169409X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addr.2010.08.010     Document Type: Review

References (252)

1. Friedenstein A.J. Osteogenic stem cells in the bone marrow. Bone Miner. 1991, 7:243-272.
2. Friedenstein A.J., Chailakhyan R.K., Latsinik N.V., Panasyuk A.F., Keiliss-Borok I.V. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. Transplantation 1974, 17(4):331-340.
3. Caplan A.I. Mesenchymal stem cells. J. Orthop. Res. 1991, 9(5):641-650.
4. Galotto M., Berisso G., Delfino L., Podesta M., Ottaggio L., Dallorso S., Dufour C., Ferrara G.B., Abbondandolo A., Dini G., Bacigalupo A., Cancedda R., Quarto R. Stromal damage as consequence of high-dose chemo/radiotherapy in bone marrow transplant recipients. Exp. Hematol. 1999, 27(9):1460-1466.
5. Kassem M. Mesenchymal stem cells: biological characteristics and potential clinical applications. Cloning Stem Cells 2004, 6(4):369-374.
6. Luria E.A., Panasyuk A.F., Friedenstein A.Y. Fibroblast colony formation from monolayer cultures of blood cells. Transfusion 1971, 11(6):345-349.
7. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284(5411):143-147.
8. Simmons P.J., Torok-Storb B. Identification of stromal cell precursors in human bone marrow by a novel monoclonal antibody, STRO-1. Blood 1991, 78(1):55-62.
9. Airey J.A., Almeida-Porada G., Colletti E.J., Porada C.D., Chamberlain J., Movsesian M., Sutko J.L., Zanjani E.D. Human mesenchymal stem cells form Purkinje fibers in fetal sheep heart. Circulation 2004, 109(11):1401-1407.
10. Almeida-Porada M.G., Porada C., ElShabrawy D., Simmons P.J., Zanjani E.D. Human marrow stromal cells (MSC) represent a latent pool of stem cells capable of generating long-term hematopoietic cells. Blood 2001, 98(Part 1):713a.
11. Chamberlain J., Yamagami T., Colletti E., Theise N.D., Desai J., Frias A., Pixley J., Zanjani E.D., Porada C.D., Almeida-Porada G. Efficient generation of human hepatocytes by the intrahepatic delivery of clonal human mesenchymal stem cells in fetal sheep. Hepatology 2007, 46(6):1935-1945.
12. Colletti E., Zanjani E.D., Porada C.D., Almeida-Porada M.G. Tales from the crypt: mesenchymal stem cells for replenishing the intestinal stem cell pool. Blood 2008, 112. Abstract 390.
13. Colletti E.J., A.J.A., Zanjani E.D., Porada C.D., Almeida-Porada G. Human mesenchymal stem cells differentiate promptly into tissue-specific cell types without cell fusion, mitochondrial or membrane vesicular transfer in fetal sheep. Blood 2007, 110(11):135a.
14. Colletti E.J., Airey J.A., Liu W., Simmons P.J., Zanjani E.D., Porada C.D., Almeida-Porada G. Generation of tissue-specific cells from MSC does not require fusion or donor-to-host mitochondrial/membrane transfer. Stem Cell Res. 2009, 2(2):125-138.
15. Colletti E.J., Almeida-Porada G., Chamberlain J., Zanjani E.D., Airey J.A. The time course of engraftment of human mesenchymal stem cells in fetal heart demonstrates that Purkinje fiber aggregates derive from a single cell and not multi-cell homing. Exp. Hematol. 2006, 34(7):926-933.
16. Bruder S.P., Ricalton N.S., Boynton R.E., Connolly T.J., Jaiswal N., Zaia J., Barry F.P. Mesenchymal stem cell surface antigen SB-10 corresponds to activated leukocyte cell adhesion molecule and is involved in osteogenic differentiation. J. Bone Miner. Res. 1998, 13(4):655-663.
17. Haynesworth S.E., Baber M.A., Caplan A.I. Cell surface antigens on human marrow-derived mesenchymal cells are detected by monoclonal antibodies. Bone 1992, 13(1):69-80.
18. Mitchell J.B., McIntosh K., Zvonic S., Garrett S., Floyd Z.E., Kloster A., Di Halvorsen Y., Storms R.W., Goh B., Kilroy G., Wu X., Gimble J.M. Immunophenotype of human adipose-derived cells: temporal changes in stromal-associated and stem cell-associated markers. Stem Cells 2006, 24(2):376-385.
19. Almeida-Porada G., El Shabrawy D., Porada C., Zanjani E.D. Differentiative potential of human metanephric mesenchymal cells. Exp. Hematol. 2002, 30(12):1454-1462.
20. Fan C.G., Tang F.W., Zhang Q.J., Lu S.H., Liu H.Y., Zhao Z.M., Liu B., Han Z.B., Han Z.C. Characterization and neural differentiation of fetal lung mesenchymal stem cells. Cell Transplant. 2005, 14(5):311-321.
21. Gotherstrom C., West A., Liden J., Uzunel M., Lahesmaa R., Le Blanc K. Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica 2005, 90(8):1017-1026.
22. in 't Anker P.S., Noort W.A., Scherjon S.A., Kleijburg-van der Keur C., Kruisselbrink A.B., van Bezooijen R.L., Beekhuizen W., Willemze R., Kanhai H.H., Fibbe W.E. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 2003, 88(8):845-852.
23. Lee O.K., Kuo T.K., Chen W.M., Lee K.D., Hsieh S.L., Chen T.H. Isolation of multipotent mesenchymal stem cells from umbilical cord blood. Blood 2004, 103(5):1669-1675.
24. Morizono K., De Ugarte D.A., Zhu M., Zuk P., Elbarbary A., Ashjian P., Benhaim P., Chen I.S., Hedrick M.H. Multilineage cells from adipose tissue as gene delivery vehicles. Hum. Gene Ther. 2003, 14(1):59-66.
25. Zuk P.A., Zhu M., Ashjian P., De Ugarte D.A., Huang J.I., Mizuno H., Alfonso Z.C., Fraser J.K., Benhaim P., Hedrick M.H. Human adipose tissue is a source of multipotent stem cells. Mol. Biol. Cell 2002, 13(12):4279-4295.
26. Zuk P.A., Zhu M., Mizuno H., Huang J., Futrell J.W., Katz A.J., Benhaim P., Lorenz H.P., Hedrick M.H. Multilineage cells from human adipose tissue: implications for cell-based therapies. Tissue Eng. 2001, 7(2):211-228.
27. Garol N.J., Yamagami T., Osborne C., Porada C.D., Zanjani E.D., Almeida-Porada G. Tissue-specific molecular signature may explain differentiative bias of human MSC from different tissues. Blood 2007, 110(11):570a.
28. Mazhari S., Desai J., Chamberlain J., Porada C., Zanjani E.D., Almeida-Porada G. Proteomic analysis reveals intrinsic differences between phenotypically identical mesenchymal stem cells. Blood 2005, 106(11).
29. Mazhari S.M., Porada C.D., Chamberlain J., Zanjani E.D., Almeida-Porada G. Characterization of membrane proteins of mesenchymal stem cells from human liver. Exp. Hematol. 2006, 34(9, Suppl. 1):80.
30. Lee R.H., Kim B., Choi I., Kim H., Choi H.S., Suh K., Bae Y.C., Jung J.S. Characterization and expression analysis of mesenchymal stem cells from human bone marrow and adipose tissue. Cell. Physiol. Biochem. 2004, 14(4-6):311-324.
31. Kern S., Eichler H., Stoeve J., Kluter H., Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006, 24(5):1294-1301.
32. Chamberlain J., Frias A., Porada C., Zanjani E.D., Almeida-Porada G. Neural generation in vivo differs with route of administration and source of mesenchymal stem cells. Exp. Hematol. 2005, 33(7):47a.
33. Almeida-Porada M.G., Chamberlain J., Frias A., Porada C.D., Zanjani E.D. Tissue of origin influences in vivo differentiative potential of mesenchymal stem cells. Blood 2003, 102(11). abstract #1304.
34. Bernardo M.E., Zaffaroni N., Novara F., Cometa A.M., Avanzini M.A., Moretta A., Montagna D., Maccario R., Villa R., Daidone M.G., Zuffardi O., Locatelli F. Human bone marrow derived mesenchymal stem cells do not undergo transformation after long-term in vitro culture and do not exhibit telomere maintenance mechanisms. Cancer Res. 2007, 67(19):9142-9149.
35. Bochkov N.P., Voronina E.S., Kosyakova N.V., Liehr T., Rzhaninova A.A., Katosova L.D., Platonova V.I., Gol'dshtein D.V. Chromosome variability of human multipotent mesenchymal stromal cells. Bull. Exp. Biol. Med. 2007, 143(1):122-126.
36. Buyanovskaya O.A., Kuleshov N.P., Nikitina V.A., Voronina E.S., Katosova L.D., Bochkov N.P. Spontaneous aneuploidy and clone formation in adipose tissue stem cells during different periods of culturing. Bull. Exp. Biol. Med. 2009, 148(1):109-112.
37. Rubio D., Garcia S., De la Cueva T., Paz M.F., Lloyd A.C., Bernad A., Garcia-Castro J. Human mesenchymal stem cell transformation is associated with a mesenchymal-epithelial transition. Exp. Cell Res. 2008, 314(4):691-698.
38. Rubio D., Garcia-Castro J., Martin M.C., de la Fuente R., Cigudosa J.C., Lloyd A.C., Bernad A. Spontaneous human adult stem cell transformation. Cancer Res. 2005, 65(8):3035-3039.
39. Altanerova V., Horvathova E., Matuskova M., Kucerova L., Altaner C. Genotoxic damage of human adipose-tissue derived mesenchymal stem cells triggers their terminal differentiation. Neoplasma 2009, 56(6):542-547.
40. Crop M., Baan C., Weimar W., Hoogduijn M. Potential of mesenchymal stem cells as immune therapy in solid-organ transplantation. Transpl. Int. 2009, 22(4):365-376.
41. de Jong D.S., Vaes B.L., Dechering K.J., Feijen A., Hendriks J.M., Wehrens R., Mummery C.L., van Zoelen E.J., Olijve W., Steegenga W.T. Identification of novel regulators associated with early-phase osteoblast differentiation. J. Bone Miner. Res. 2004, 19(6):947-958.
42. Hishikawa K., Miura S., Marumo T., Yoshioka H., Mori Y., Takato T., Fujita T. Gene expression profile of human mesenchymal stem cells during osteogenesis in three-dimensional thermoreversible gelation polymer. Biochem. Biophys. Res. Commun. 2004, 317(4):1103-1107.
43. Nakamura T., Shiojima S., Hirai Y., Iwama T., Tsuruzoe N., Hirasawa A., Katsuma S., Tsujimoto G. Temporal gene expression changes during adipogenesis in human mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2003, 303(1):306-312.
44. Ando W., Tateishi K., Hart D.A., Katakai D., Tanaka Y., Nakata K., Hashimoto J., Fujie H., Shino K., Yoshikawa H., Nakamura N. Cartilage repair using an in vitro generated scaffold-free tissue-engineered construct derived from porcine synovial mesenchymal stem cells. Biomaterials 2007, 28(36):5462-5470.
45. Cancedda R., Mastrogiacomo M., Bianchi G., Derubeis A., Muraglia A., Quarto R. Bone marrow stromal cells and their use in regenerating bone. Novartis Found. Symp. 2003, 249:133-143. discussion 143-7, 170-4, 239-41.
46. Quarto R., Mastrogiacomo M., Cancedda R., Kutepov S.M., Mukhachev V., Lavroukov A., Kon E., Marcacci M. Repair of large bone defects with the use of autologous bone marrow stromal cells. N Engl J. Med. 2001, 344(5):385-386.
47. Wakitani S., Mitsuoka T., Nakamura N., Toritsuka Y., Nakamura Y., Horibe S. Autologous bone marrow stromal cell transplantation for repair of full-thickness articular cartilage defects in human patellae: two case reports. Cell Transplant. 2004, 13(5):595-600.
48. Horwitz E.M., Gordon P.L., Koo W.K., Marx J.C., Neel M.D., McNall R.Y., Muul L., Hofmann T. Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc. Natl Acad. Sci. USA 2002, 99(13):8932-8937.
49. Horwitz E.M., Prockop D.J., Fitzpatrick L.A., Koo W.W., Gordon P.L., Neel M., Sussman M., Orchard P., Marx J.C., Pyeritz R.E., Brenner M.K. Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat. Med. 1999, 5(3):309-313.
50. Horwitz E.M., Prockop D.J., Gordon P.L., Koo W.W., Fitzpatrick L.A., Neel M.D., McCarville M.E., Orchard P.J., Pyeritz R.E., Brenner M.K. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001, 97(5):1227-1231.
51. Le Blanc K., Gotherstrom C., Ringden O., Hassan M., McMahon R., Horwitz E., Anneren G., Axelsson O., Nunn J., Ewald U., Norden-Lindeberg S., Jansson M., Dalton A., Astrom E., Westgren M. Fetal mesenchymal stem-cell engraftment in bone after in utero transplantation in a patient with severe osteogenesis imperfecta. Transplantation 2005, 79(11):1607-1614.
52. Wakitani S., Saito T., Caplan A.I. Myogenic cells derived from rat bone marrow mesenchymal stem cells exposed to 5-azacytidine. Muscle Nerve 1995, 18(12):1417-1426.
53. Dezawa M., Ishikawa H., Itokazu Y., Yoshihara T., Hoshino M., Takeda S., Ide C., Nabeshima Y. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 2005, 309(5732):314-317.
54. Ichim T.E., Alexandrescu D.T., Solano F., Lara F., Campion Rde N., Paris E., Woods E.J., Murphy M.P., Dasanu C.A., Patel A.N., Marleau A.M., Leal A., Riordan N.H. Mesenchymal stem cells as anti-inflammatories: implications for treatment of Duchenne muscular dystrophy. Cell Immunol. 2010, 260(2):75-82.
55. Bossolasco P., Cova L., Calzarossa C., Rimoldi S.G., Borsotti C., Deliliers G.L., Silani V., Soligo D., Polli E. Neuro-glial differentiation of human bone marrow stem cells in vitro. Exp. Neurol. 2005, 193(2):312-325.
56. Brazelton T.R., Rossi F.M., Keshet G.I., Blau H.M. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000, 290(5497):1775-1779.
57. Kopen G.C., Prockop D.J., Phinney D.G. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc. Natl Acad. Sci. USA 1999, 96(19):10711-10716.
58. Mezey E., Chandross K.J., Harta G., Maki R.A., McKercher S.R. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000, 290(5497):1779-1782.
59. Hofstetter C.P., Schwarz E.J., Hess D., Widenfalk J., El Manira A., Prockop D.J., Olson L. Marrow stromal cells form guiding strands in the injured spinal cord and promote recovery. Proc. Natl Acad. Sci. USA 2002, 99(4):2199-2204.
60. Neuhuber B., Timothy Himes B., Shumsky J.S., Gallo G., Fischer I. Axon growth and recovery of function supported by human bone marrow stromal cells in the injured spinal cord exhibit donor variations. Brain Res. 2005, 1035(1):73-85.
61. Satake K., Lou J., Lenke L.G. Migration of mesenchymal stem cells through cerebrospinal fluid into injured spinal cord tissue. Spine 2004, 29(18):1971-1979. (Phila Pa 1976).
62. Honma T., Honmou O., Iihoshi S., Harada K., Houkin K., Hamada H., Kocsis J.D. Intravenous infusion of immortalized human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Exp. Neurol. 2006, 199(1):56-66.
63. Kang S.K., Lee D.H., Bae Y.C., Kim H.K., Baik S.Y., Jung J.S. Improvement of neurological deficits by intracerebral transplantation of human adipose tissue-derived stromal cells after cerebral ischemia in rats. Exp. Neurol. 2003, 183(2):355-366.
64. Nomura T., Honmou O., Harada K., Houkin K., Hamada H., Kocsis J.D. I.V. infusion of brain-derived neurotrophic factor gene-modified human mesenchymal stem cells protects against injury in a cerebral ischemia model in adult rat. Neuroscience 2005, 136(1):161-169.
65. Chen J., Li Y., Katakowski M., Chen X., Wang L., Lu D., Lu M., Gautam S.C., Chopp M. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J. Neurosci. Res. 2003, 73(6):778-786.
66. Chen J., Li Y., Wang L., Lu M., Zhang X., Chopp M. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J. Neurol. Sci. 2001, 189(1-2):49-57.
67. Chen J., Zhang Z.G., Li Y., Wang L., Xu Y.X., Gautam S.C., Lu M., Zhu Z., Chopp M. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ. Res. 2003, 92(6):692-699.
68. Iihoshi S., Honmou O., Houkin K., Hashi K., Kocsis J.D. A therapeutic window for intravenous administration of autologous bone marrow after cerebral ischemia in adult rats. Brain Res. 2004, 1007(1-2):1-9.
69. Kurozumi K., Nakamura K., Tamiya T., Kawano Y., Ishii K., Kobune M., Hirai S., Uchida H., Sasaki K., Ito Y., Kato K., Honmou O., Houkin K., Date I., Hamada H. Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol. Ther. 2005, 11(1):96-104.
70. Kurozumi K., Nakamura K., Tamiya T., Kawano Y., Kobune M., Hirai S., Uchida H., Sasaki K., Ito Y., Kato K., Honmou O., Houkin K., Date I., Hamada H. BDNF gene-modified mesenchymal stem cells promote functional recovery and reduce infarct size in the rat middle cerebral artery occlusion model. Mol. Ther. 2004, 9(2):189-197.
71. Li Y., Chen J., Chen X.G., Wang L., Gautam S.C., Xu Y.X., Katakowski M., Zhang L.J., Lu M., Janakiraman N., Chopp M. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology 2002, 59(4):514-523.
72. Zheng W., Honmou O., Miyata K., Harada K., Suzuki J., Liu H., Houkin K., Hamada H., Kocsis J.D. Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res. 2010, 1310:8-16.
73. Akiyama Y., Radtke C., Kocsis J.D. Remyelination of the rat spinal cord by transplantation of identified bone marrow stromal cells. J. Neurosci. 2002, 22(15):6623-6630.
74. Akiyama Y., Radtke C., Honmou O., Kocsis J.D. Remyelination of the spinal cord following intravenous delivery of bone marrow cells. Glia 2002, 39(3):229-236.
75. Gerdoni E., Gallo B., Casazza S., Musio S., Bonanni I., Pedemonte E., Mantegazza R., Frassoni F., Mancardi G., Pedotti R., Uccelli A. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann. Neurol. 2007, 61(3):219-227.
76. Jin H.K., Carter J.E., Huntley G.W., Schuchman E.H. Intracerebral transplantation of mesenchymal stem cells into acid sphingomyelinase-deficient mice delays the onset of neurological abnormalities and extends their life span. J. Clin. Invest. 2002, 109(9):1183-1191.
77. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 2005, 106(5):1755-1761.
78. Blandini F., Cova L., Armentero M.T., Zennaro E., Levandis G., Bossolasco P., Calzarossa C., Mellone M., Giuseppe B., Deliliers G.L., Polli E., Nappi G., Silani V. Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant. 2009, 19(2):203-217.
79. Cova L., Armentero M.T., Zennaro E., Calzarossa C., Bossolasco P., Busca G., Lambertenghi Deliliers G., Polli E., Nappi G., Silani V., Blandini F. Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson's disease. Brain Res. 2010, 1311:12-27.
80. Li Y., Chen J., Wang L., Zhang L., Lu M., Chopp M. Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci. Lett. 2001, 316(2):67-70.
81. Mahmood A., Lu D., Lu M., Chopp M. Treatment of traumatic brain injury in adult rats with intravenous administration of human bone marrow stromal cells. Neurosurgery 2003, 53(3):697-702. discussion 702-3.
82. Phinney D.G., Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr. Pharm. Des. 2005, 11(10):1255-1265.
83. Pisati F., Bossolasco P., Meregalli M., Cova L., Belicchi M., Gavina M., Marchesi C., Calzarossa C., Soligo D., Lambertenghi-Deliliers G., Bresolin N., Silani V., Torrente Y., Polli E. Induction of neurotrophin expression via human adult mesenchymal stem cells: implication for cell therapy in neurodegenerative diseases. Cell Transplant. 2007, 16(1):41-55.
84. Prockop D.J., Azizi S.A., Phinney D.G., Kopen G.C., Schwarz E.J. Potential use of marrow stromal cells as therapeutic vectors for diseases of the central nervous system. Prog. Brain Res. 2000, 128:293-297.
85. Tondreau T., Lagneaux L., Dejeneffe M., Massy M., Mortier C., Delforge A., Bron D. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 2004, 72(7):319-326.
86. Fukuda K. Reprogramming of bone marrow mesenchymal stem cells into cardiomyocytes. C R Biol. 2002, 325(10):1027-1038.
87. Shim W.S., Jiang S., Wong P., Tan J., Chua Y.L., Tan Y.S., Sin Y.K., Lim C.H., Chua T., Teh M., Liu T.C., Sim E. Ex vivo differentiation of human adult bone marrow stem cells into cardiomyocyte-like cells. Biochem. Biophys. Res. Commun. 2004, 324(2):481-488.
88. Xu W., Zhang X., Qian H., Zhu W., Sun X., Hu J., Zhou H., Chen Y. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp. Biol. Med. 2004, 229(7):623-631. (Maywood).
89. Cao Y., Sun Z., Liao L., Meng Y., Han Q., Zhao R.C. Human adipose tissue-derived stem cells differentiate into endothelial cells in vitro and improve postnatal neovascularization in vivo. Biochem. Biophys. Res. Commun. 2005, 332(2):370-379.
90. Toma C., Pittenger M.F., Cahill K.S., Byrne B.J., Kessler P.D. Human mesenchymal stem cells differentiate to a cardiomyocyte phenotype in the adult murine heart. Circulation 2002, 105(1):93-98.
91. Tomita S., Mickle D.A., Weisel R.D., Jia Z.Q., Tumiati L.C., Allidina Y., Liu P., Li R.K. Improved heart function with myogenesis and angiogenesis after autologous porcine bone marrow stromal cell transplantation. J. Thorac. Cardiovasc. Surg. 2002, 123(6):1132-1140.
92. Yoon J., Min B.G., Kim Y.H., Shim W.J., Ro Y.M., Lim D.S. Differentiation, engraftment and functional effects of pre-treated mesenchymal stem cells in a rat myocardial infarct model. Acta Cardiol. 2005, 60(3):277-284.
93. Huang J., Zhang Z., Guo J., Ni A., Deb A., Zhang L., Mirotsou M., Pratt R.E., Dzau V.J. Genetic modification of mesenchymal stem cells overexpressing ccr1 increases cell viability, migration, engraftment, and capillary density in the injured myocardium. Circ. Res. 2010, 106(11):1753-1762.
94. Jiang W., Ma A., Wang T., Han K., Liu Y., Zhang Y., Dong A., Du Y., Huang X., Wang J., Lei X., Zheng X. Homing and differentiation of mesenchymal stem cells delivered intravenously to ischemic myocardium in vivo: a time-series study. Pfluegers Arch. 2006, 453(1):43-52.
95. Jiang W., Ma A., Wang T., Han K., Liu Y., Zhang Y., Zhao X., Dong A., Du Y., Huang X., Wang J., Lei X., Zheng X. Intravenous transplantation of mesenchymal stem cells improves cardiac performance after acute myocardial ischemia in female rats. Transpl. Int. 2006, 19(7):570-580.
96. Jiang W.H., Ma A.Q., Zhang Y.M., Han K., Liu Y., Zhang Z.T., Wang T.Z., Huang X., Zheng X.P. Migration of intravenously grafted mesenchymal stem cells to injured heart in rats. Sheng Li Xue Bao 2005, 57(5):566-572.
97. Katritsis D.G., Sotiropoulou P., Giazitzoglou E., Karvouni E., Papamichail M. Electrophysiological effects of intracoronary transplantation of autologous mesenchymal and endothelial progenitor cells. Europace 2007, 9(3):167-171.
98. Li Q., Turdi S., Thomas D.P., Zhou T., Ren J. Intra-myocardial delivery of mesenchymal stem cells ameliorates left ventricular and cardiomyocyte contractile dysfunction following myocardial infarction. Toxicol. Lett. 2010, 195(2-3):119-126.
99. Ohnishi S., Yanagawa B., Tanaka K., Miyahara Y., Obata H., Kataoka M., Kodama M., Ishibashi-Ueda H., Kangawa K., Kitamura S., Nagaya N. Transplantation of mesenchymal stem cells attenuates myocardial injury and dysfunction in a rat model of acute myocarditis. J. Mol. Cell. Cardiol. 2007, 42(1):88-97.
100. Orlic D., Kajstura J., Chimenti S., Limana F., Jakoniuk I., Quaini F., Nadal-Ginard B., Bodine D.M., Leri A., Anversa P. Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc. Natl Acad. Sci. USA 2001, 98(18):10344-10349.
101. Song H., Song B.W., Cha M.J., Choi I.G., Hwang K.C. Modification of mesenchymal stem cells for cardiac regeneration. Expert Opin. Biol. Ther. 2010, 10(3):309-319.
102. Tang J., Wang J., Guo L., Kong X., Yang J., Zheng F., Zhang L., Huang Y. Mesenchymal stem cells modified with stromal cell-derived factor 1 alpha improve cardiac remodeling via paracrine activation of hepatocyte growth factor in a rat model of myocardial infarction. Mol. Cells 2010, 29(1):9-19.
103. Westrich J., Yaeger P., He C., Stewart J., Chen R., Seleznik G., Larson S., Wentworth B., O'Callaghan M., Wadsworth S., Akita G., Molnar G. Factors affecting residence time of mesenchymal stromal cells (MSC) injected into the myocardium. Cell Transplant. March 31 2010, [epub ahead of print].
104. Xu J., Chen Q., Shi C., Yin Z. Overexpression of CXCR1/CXCR2 on mesenchymal stromal cells may be an effective treatment for acute myocardial infarction. Cytotherapy 2009, 11(8):990-991.
105. Yau T.M., Tomita S., Weisel R.D., Jia Z.Q., Tumiati L.C., Mickle D.A., Li R.K. Beneficial effect of autologous cell transplantation on infarcted heart function: comparison between bone marrow stromal cells and heart cells. Ann. Thorac. Surg. 2003, 75(1):169-176. discussion 176-7.
106. Quevedo H.C., Hatzistergos K.E., Oskouei B.N., Feigenbaum G.S., Rodriguez J.E., Valdes D., Pattany P.M., Zambrano J.P., Hu Q., McNiece I., Heldman A.W., Hare J.M. Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc. Natl Acad. Sci. USA 2009, 106(33):14022-14027.
107. Kogler G., Sensken S., Airey J.A., Trapp T., Muschen M., Feldhahn N., Liedtke S., Sorg R.V., Fischer J., Rosenbaum C., Greschat S., Knipper A., Bender J., Degistirici O., Gao J., Caplan A.I., Colletti E.J., Almeida-Porada G., Muller H.W., Zanjani E., Wernet P. A new human somatic stem cell from placental cord blood with intrinsic pluripotent differentiation potential. J. Exp. Med. 2004, 200(2):123-135.
108. Noort W.A., Feye D., Van Den Akker F., Stecher D., Chamuleau S.A., Sluijter J.P., Doevendans P.A. Mesenchymal stromal cells to treat cardiovascular disease: strategies to improve survival and therapeutic results. Panminerva Med. 2010, 52(1):27-40.
109. Rameshwar P., Qiu H., Vatner S.F. Stem cells in cardiac repair in an inflammatory microenvironment. Minerva Cardioangiol. 2010, 58(1):127-146.
110. Kocher A.A., Schlechta B., Gasparovicova A., Wolner E., Bonaros N., Laufer G. Stem cells and cardiac regeneration. Transpl. Int. 2007, 20(9):731-746.
111. Hare J.M., Traverse J.H., Henry T.D., Dib N., Strumpf R.K., Schulman S.P., Gerstenblith G., DeMaria A.N., Denktas A.E., Gammon R.S., Hermiller J.B., Reisman M.A., Schaer G.L., Sherman W. A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J. Am. Coll. Cardiol. 2009, 54(24):2277-2286.
112. Mohyeddin-Bonab M., Mohamad-Hassani M.R., Alimoghaddam K., Sanatkar M., Gasemi M., Mirkhani H., Radmehr H., Salehi M., Eslami M., Farhig-Parsa A., Emami-Razavi H., Alemohammad M.G., Solimani A.A., Ghavamzadeh A., Nikbin B. Autologous in vitro expanded mesenchymal stem cell therapy for human old myocardial infarction. Arch. Iran. Med. 2007, 10(4):467-473.
113. Ripa R.S., Haack-Sorensen M., Wang Y., Jorgensen E., Mortensen S., Bindslev L., Friis T., Kastrup J. Bone marrow derived mesenchymal cell mobilization by granulocyte-colony stimulating factor after acute myocardial infarction: results from the Stem Cells in Myocardial Infarction (STEMMI) trial. Circulation 2007, 116(11 Suppl):I24-I30.
114. Hoogduijn M.J., Crop M.J., Peeters A.M., Korevaar S.S., Eijken M., Drabbels J.J., Roelen D.L., Maat A.P., Balk A.H., Weimar W., Baan C.C. Donor-derived mesenchymal stem cells remain present and functional in the transplanted human heart. Am. J. Transplant. 2009, 9(1):222-230.
115. Chen S.L., Fang W.W., Qian J., Ye F., Liu Y.H., Shan S.J., Zhang J.J., Lin S., Liao L.M., Zhao R.C. Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin. Med. J. (Engl) 2004, 117(10):1443-1448.
116. Chen S.L., Fang W.W., Ye F., Liu Y.H., Qian J., Shan S.J., Zhang J.J., Chunhua R.Z., Liao L.M., Lin S., Sun J.P. Effect on left ventricular function of intracoronary transplantation of autologous bone marrow mesenchymal stem cell in patients with acute myocardial infarction. Am. J. Cardiol. 2004, 94(1):92-95.
117. Lee K.D., Kuo T.K., Whang-Peng J., Chung Y.F., Lin C.T., Chou S.H., Chen J.R., Chen Y.P., Lee O.K. In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology 2004, 40(6):1275-1284.
118. Sato Y., Araki H., Kato J., Nakamura K., Kawano Y., Kobune M., Sato T., Miyanishi K., Takayama T., Takahashi M., Takimoto R., Iyama S., Matsunaga T., Ohtani S., Matsuura A., Hamada H., Niitsu Y. Human mesenchymal stem cells xenografted directly to rat liver are differentiated into human hepatocytes without fusion. Blood 2005, 106(2):756-763.
119. Schwartz R.E., Reyes M., Koodie L., Jiang Y., Blackstad M., Lund T., Lenvik T., Johnson S., Hu W.S., Verfaillie C.M. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J. Clin. Invest. 2002, 109(10):1291-1302.
120. Almeida-Porada G., Porada C., Zanjani E.D. Adult stem cell plasticity and methods of detection. Rev. Clin. Exp. Hematol. 2001, 5(1):26-41.
121. Almeida-Porada G., Porada C., Zanjani E.D. Plasticity of human stem cells in the fetal sheep model of human stem cell transplantation. Int. J. Hematol. 2004, 79(1):1-6.
122. Almeida-Porada G., Zanjani E.D. A large animal noninjury model for study of human stem cell plasticity. Blood Cells Mol. Dis. 2004, 32(1):77-81.
123. Aurich H., Sgodda M., Kaltwasser P., Vetter M., Weise A., Liehr T., Brulport M., Hengstler J.G., Dollinger M.M., Fleig W.E., Christ B. Hepatocyte differentiation of mesenchymal stem cells from human adipose tissue in vitro promotes hepatic integration in vivo. Gut 2008, 58(4):570-581.
124. Aurich I., Mueller L.P., Aurich H., Luetzkendorf J., Tisljar K., Dollinger M.M., Schormann W., Walldorf J., Hengstler J.G., Fleig W.E., Christ B. Functional integration of hepatocytes derived from human mesenchymal stem cells into mouse livers. Gut 2007, 56(3):405-415.
125. Banas A., Teratani T., Yamamoto Y., Tokuhara M., Takeshita F., Osaki M., Kato T., Okochi H., Ochiya T. Rapid hepatic fate specification of adipose-derived stem cells and their therapeutic potential for liver failure. J. Gastroenterol. Hepatol. 2008, 24(1):70-77.
126. Banas A., Teratani T., Yamamoto Y., Tokuhara M., Takeshita F., Osaki M., Kawamata M., Kato T., Okochi H., Ochiya T. IFATS collection: in vivo therapeutic potential of human adipose tissue mesenchymal stem cells after transplantation into mice with liver injury. Stem Cells 2008, 26(10):2705-2712.
127. Banas A., Teratani T., Yamamoto Y., Tokuhara M., Takeshita F., Quinn G., Okochi H., Ochiya T. Adipose tissue-derived mesenchymal stem cells as a source of human hepatocytes. Hepatology 2007, 46(1):219-228.
128. di Bonzo L.V., Ferrero I., Cravanzola C., Mareschi K., Rustichell D., Novo E., Sanavio F., Cannito S., Zamara E., Bertero M., Davit A., Francica S., Novelli F., Colombatto S., Fagioli F., Parola M. Human mesenchymal stem cells as a two-edged sword in hepatic regenerative medicine: engraftment and hepatocyte differentiation versus profibrogenic potential. Gut 2008, 57(2):223-231.
129. Enns G.M., Millan M.T. Cell-based therapies for metabolic liver disease. Mol. Genet. Metab. 2008, 95(1-2):3-10.
130. Fang B., Shi M., Liao L., Yang S., Liu Y., Zhao R.C. Systemic infusion of FLK1(+) mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation 2004, 78(1):83-88.
131. Higashiyama R., Inagaki Y., Hong Y.Y., Kushida M., Nakao S., Niioka M., Watanabe T., Okano H., Matsuzaki Y., Shiota G., Okazaki I. Bone marrow-derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in mice. Hepatology 2007, 45(1):213-222.
132. Ishikawa T., Terai S., Urata Y., Marumoto Y., Aoyama K., Sakaida I., Murata T., Nishina H., Shinoda K., Uchimura S., Hamamoto Y., Okita K. Fibroblast growth factor 2 facilitates the differentiation of transplanted bone marrow cells into hepatocytes. Cell Tissue Res. 2006, 323(2):221-231.
133. Luk J.M., Wang P.P., Lee C.K., Wang J.H., Fan S.T. Hepatic potential of bone marrow stromal cells: development of in vitro co-culture and intra-portal transplantation models. J. Immunol. Methods 2005, 305(1):39-47.
134. Lysy P.A., Campard D., Smets F., Malaise J., Mourad M., Najimi M., Sokal E.M. Persistence of a chimerical phenotype after hepatocyte differentiation of human bone marrow mesenchymal stem cells. Cell Prolif. 2008, 41(1):36-58.
135. Muraca M., Ferraresso C., Vilei M.T., Granato A., Quarta M., Cozzi E., Rugge M., Pauwelyn K.A., Caruso M., Avital I., Inderbitzin D., Demetriou A.A., Forbes S.J., Realdi G. Liver repopulation with bone marrow derived cells improves the metabolic disorder in the Gunn rat. Gut 2007, 56(12):1725-1735.
136. Oyagi S., Hirose M., Kojima M., Okuyama M., Kawase M., Nakamura T., Ohgushi H., Yagi K. Therapeutic effect of transplanting HGF-treated bone marrow mesenchymal cells into CCl4-injured rats. J. Hepatol. 2006, 44(4):742-748.
137. Popp F.C., Piso P., Schlitt H.J., Dahlke M.H. Therapeutic potential of bone marrow stem cells for liver diseases. Curr. Stem Cell Res. Ther. 2006, 1(3):411-418.
138. Sakaida I., Terai S., Yamamoto N., Aoyama K., Ishikawa T., Nishina H., Okita K. Transplantation of bone marrow cells reduces CCl4-induced liver fibrosis in mice. Hepatology 2004, 40(6):1304-1311.
139. Sgodda M., Aurich H., Kleist S., Aurich I., Konig S., Dollinger M.M., Fleig W.E., Christ B. Hepatocyte differentiation of mesenchymal stem cells from rat peritoneal adipose tissue in vitro and in vivo. Exp. Cell Res. 2007, 313(13):2875-2886.
140. Talens-Visconti R., Bonora A., Jover R., Mirabet V., Carbonell F., Castell J.V., Gomez-Lechon M.J. Hepatogenic differentiation of human mesenchymal stem cells from adipose tissue in comparison with bone marrow mesenchymal stem cells. World J. Gastroenterol. 2006, 12(36):5834-5845.
141. Theise N.D., Krause D.S. Bone marrow to liver: the blood of Prometheus. Semin. Cell Dev. Biol. 2002, 13(6):411-417.
142. Zhao D.C., Lei J.X., Chen R., Yu W.H., Zhang X.M., Li S.N., Xiang P. Bone marrow-derived mesenchymal stem cells protect against experimental liver fibrosis in rats. World J. Gastroenterol. 2005, 11(22):3431-3440.
143. Zheng J.F., Liang L.J. Intra-portal transplantation of bone marrow stromal cells ameliorates liver fibrosis in mice. Hepatobiliary Pancreat. Dis. Int. 2008, 7(3):264-270.
144. Mohamadnejad M., Alimoghaddam K., Mohyeddin-Bonab M., Bagheri M., Bashtar M., Ghanaati H., Baharvand H., Ghavamzadeh A., Malekzadeh R. Phase 1 trial of autologous bone marrow mesenchymal stem cell transplantation in patients with decompensated liver cirrhosis. Arch. Iran. Med. 2007, 10(4):459-466.
145. Mohamadnejad M., Namiri M., Bagheri M., Hashemi S.M., Ghanaati H., Zare Mehrjardi N., Kazemi Ashtiani S., Malekzadeh R., Baharvand H. Phase 1 human trial of autologous bone marrow-hematopoietic stem cell transplantation in patients with decompensated cirrhosis. World J. Gastroenterol. 2007, 13(24):3359-3363.
146. Terai S., Ishikawa T., Omori K., Aoyama K., Marumoto Y., Urata Y., Yokoyama Y., Uchida K., Yamasaki T., Fujii Y., Okita K., Sakaida I. Improved liver function in patients with liver cirrhosis after autologous bone marrow cell infusion therapy. Stem Cells 2006, 24(10):2292-2298.
147. Parekkadan B., van Poll D., Megeed Z., Kobayashi N., Tilles A.W., Berthiaume F., Yarmush M.L. Immunomodulation of activated hepatic stellate cells by mesenchymal stem cells. Biochem. Biophys. Res. Commun. 2007, 363(2):247-252.
148. Parekkadan B., van Poll D., Suganuma K., Carter E.A., Berthiaume F., Tilles A.W., Yarmush M.L. Mesenchymal stem cell-derived molecules reverse fulminant hepatic failure. PLoS ONE 2007, 2(9):e941.
149. Kuo T.K., Hung S.P., Chuang C.H., Chen C.T., Shih Y.R., Fang S.C., Yang V.W., Lee O.K. Stem cell therapy for liver disease: parameters governing the success of using bone marrow mesenchymal stem cells. Gastroenterology 2008, 134(7):2111-2121. 2121 e1-3.
150. Caplan A.I., Dennis J.E. Mesenchymal stem cells as trophic mediators. J. Cell. Biochem. 2006, 98(5):1076-1084.
151. Haynesworth S.E., Baber M.A., Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J. Cell. Physiol. 1996, 166(3):585-592.
152. Chen T.S., Lai R.C., Lee M.M., Choo A.B., Lee C.N., Lim S.K. Mesenchymal stem cell secretes microparticles enriched in pre-microRNAs. Nucleic Acids Res. 2010, 38(1):215-224.
153. Dai W., Hale S.L., Kloner R.A. Role of a paracrine action of mesenchymal stem cells in the improvement of left ventricular function after coronary artery occlusion in rats. Regen. Med. 2007, 2(1):63-68.
154. Gnecchi M., He H., Liang O.D., Melo L.G., Morello F., Mu H., Noiseux N., Zhang L., Pratt R.E., Ingwall J.S., Dzau V.J. Paracrine action accounts for marked protection of ischemic heart by Akt-modified mesenchymal stem cells. Nat. Med. 2005, 11(4):367-368.
155. Huang N.F., Lam A., Fang Q., Sievers R.E., Li S., Lee R.J. Bone marrow-derived mesenchymal stem cells in fibrin augment angiogenesis in the chronically infarcted myocardium. Regen. Med. 2009, 4(4):527-538.
156. Ladage D., Brixius K., Steingen C., Mehlhorn U., Schwinger R.H., Bloch W., Schmidt A. Mesenchymal stem cells induce endothelial activation via paracine mechanisms. Endothelium 2007, 14(2):53-63.
157. Lai, R.C., Arslan F., Lee M.M., Sze N.S., Choo A., Chen T.S., Salto-Tellez M., Timmers L., Lee C.N., El Oakley R.M., Pasterkamp G., de Kleijn D.P., and Lim S.K., Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. Stem Cell Res. 4 (3) (2010) 214-222.
158. Li Z., Guo J., Chang Q., Zhang A. Paracrine role for mesenchymal stem cells in acute myocardial infarction. Biol. Pharm. Bull. 2009, 32(8):1343-1346.
159. Mias C., Lairez O., Trouche E., Roncalli J., Calise D., Seguelas M.H., Ordener C., Piercecchi-Marti M.D., Auge N., Salvayre A.N., Bourin P., Parini A., Cussac D. Mesenchymal stem cells promote matrix metalloproteinase secretion by cardiac fibroblasts and reduce cardiac ventricular fibrosis after myocardial infarction. Stem Cells 2009, 27(11):2734-2743.
160. Ohnishi S., Sumiyoshi H., Kitamura S., Nagaya N. Mesenchymal stem cells attenuate cardiac fibroblast proliferation and collagen synthesis through paracrine actions. FEBS Lett. 2007, 581(21):3961-3966.
161. Shabbir A., Zisa D., Suzuki G., Lee T. Heart failure therapy mediated by the trophic activities of bone marrow mesenchymal stem cells: a noninvasive therapeutic regimen. Am. J. Physiol. Heart Circ. Physiol. 2009, 296(6):H1888-H1897.
162. Timmers L., Lim S.K., Arslan F., Armstrong J.S., Hoefer I.E., Doevendans P.A., Piek J.J., El Oakley R.M., Choo A., Lee C.N., Pasterkamp G., de Kleijn D.P. Reduction of myocardial infarct size by human mesenchymal stem cell conditioned medium. Stem Cell Res. 2007, 1(2):129-137.
163. Xiang M.X., He A.N., Wang J.A., Gui C. Protective paracrine effect of mesenchymal stem cells on cardiomyocytes. J. Zhejiang Univ. Sci. B 2009, 10(8):619-624.
164. Yu X.Y., Geng Y.J., Li X.H., Lin Q.X., Shan Z.X., Lin S.G., Song Y.H., Li Y. The effects of mesenchymal stem cells on c-kit up-regulation and cell-cycle re-entry of neonatal cardiomyocytes are mediated by activation of insulin-like growth factor 1 receptor. Mol. Cell. Biochem. 2009, 332(1-2):25-32.
165. van Poll D., Parekkadan B., Cho C.H., Berthiaume F., Nahmias Y., Tilles A.W., Yarmush M.L. Mesenchymal stem cell-derived molecules directly modulate hepatocellular death and regeneration in vitro and in vivo. Hepatology 2008, 47(5):1634-1643.
166. Abdel Aziz M.T., Atta H.M., Mahfouz S., Fouad H.H., Roshdy N.K., Ahmed H.H., Rashed L.A., Sabry D., Hassouna A.A., Hasan N.M. Therapeutic potential of bone marrow-derived mesenchymal stem cells on experimental liver fibrosis. Clin. Biochem. 2007, 40(12):893-899.
167. Li J.T., Liao Z.X., Ping J., Xu D., Wang H. Molecular mechanism of hepatic stellate cell activation and antifibrotic therapeutic strategies. J. Gastroenterol. 2008, 43(6):419-428.
168. Zhao Z.H., Xin S.J., Zhao J.M., Wang S.S., Liu P., Yin T.Y., Zhou G.D. Dynamic expression of matrix metalloproteinase-2, membrane type-matrix metalloproteinase-2 in experimental hepatic fibrosis and its reversal in rat. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2004, 18(4):328-331.
169. Alison M., Islam S., Lim S. Stem cells in liver regeneration, fibrosis and cancer: the good, the bad and the ugly. J. Pathol. 2008, 217(2):282-298.
170. Asawa S., Saito T., Satoh A., Ohtake K., Tsuchiya T., Okada H., Neilson E.G., Gotoh M. Participation of bone marrow cells in biliary fibrosis after bile duct ligation. J. Gastroenterol. Hepatol. 2007, 22(11):2001-2008.
171. Baba S., Fujii H., Hirose T., Yasuchika K., Azuma H., Hoppo T., Naito M., Machimoto T., Ikai I. Commitment of bone marrow cells to hepatic stellate cells in mouse. J. Hepatol. 2004, 40(2):255-260.
172. Kisseleva T., Uchinami H., Feirt N., Quintana-Bustamante O., Segovia J.C., Schwabe R.F., Brenner D.A. Bone marrow-derived fibrocytes participate in pathogenesis of liver fibrosis. J. Hepatol. 2006, 45(3):429-438.
173. Russo F.P., Alison M.R., Bigger B.W., Amofah E., Florou A., Amin F., Bou-Gharios G., Jeffery R., Iredale J.P., Forbes S.J. The bone marrow functionally contributes to liver fibrosis. Gastroenterology 2006, 130(6):1807-1821.
174. Ozawa K., Sato K., Oh I., Ozaki K., Uchibori R., Obara Y., Kikuchi Y., Ito T., Okada T., Urabe M., Mizukami H., Kume A. Cell and gene therapy using mesenchymal stem cells (MSCs). J. Autoimmun. 2008, 30(3):121-127.
175. Reiser J., Zhang X.Y., Hemenway C.S., Mondal D., Pradhan L., La Russa V.F. Potential of mesenchymal stem cells in gene therapy approaches for inherited and acquired diseases. Expert Opin. Biol. Ther. 2005, 5(12):1571-1584.
176. Bosch P., Fouletier-Dilling C., Olmsted-Davis E.A., Davis A.R., Stice S.L. Efficient adenoviral-mediated gene delivery into porcine mesenchymal stem cells. Mol. Reprod. Dev. 2006, 73(11):1393-1403.
177. Bosch P., Stice S.L. Adenoviral transduction of mesenchymal stem cells. Methods Mol. Biol. 2007, 407:265-274.
178. Roelants V., Labar D., de Meester C., Havaux X., Tabilio A., Gambhir S.S., Di Ianni M., Bol A., Bertrand L., Vanoverschelde J.L. Comparison between adenoviral and retroviral vectors for the transduction of the thymidine kinase PET reporter gene in rat mesenchymal stem cells. J. Nucl. Med. 2008, 49(11):1836-1844.
179. Gnecchi M., Melo L.G. Bone marrow-derived mesenchymal stem cells: isolation, expansion, characterization, viral transduction, and production of conditioned medium. Methods Mol. Biol. 2009, 482:281-294.
180. Meyerrose T.E., De Ugarte D.A., Hofling A.A., Herrbrich P.E., Cordonnier T.D., Shultz L.D., Eagon J.C., Wirthlin L., Sands M.S., Hedrick M.A., Nolta J.A. In vivo distribution of human adipose-derived mesenchymal stem cells in novel xenotransplantation models. Stem Cells 2007, 25(1):220-227.
181. Piccoli C., Scrima R., Ripoli M., Di Ianni M., Del Papa B., D'Aprile A., Quarato G., Martelli M.P., Servillo G., Ligas C., Boffoli D., Tabilio A., Capitanio N. Transformation by retroviral vectors of bone marrow-derived mesenchymal cells induces mitochondria-dependent cAMP-sensitive reactive oxygen species production. Stem Cells 2008, 26(11):2843-2854.
182. Sales V.L., Mettler B.A., Lopez-Ilasaca M., Johnson J.A., Mayer J.E. Endothelial progenitor and mesenchymal stem cell-derived cells persist in tissue-engineered patch in vivo: application of green and red fluorescent protein-expressing retroviral vector. Tissue Eng. 2007, 13(3):525-535.
183. Fan L., Lin C., Zhuo S., Chen L., Liu N., Luo Y., Fang J., Huang Z., Lin Y., Chen J. Transplantation with survivin-engineered mesenchymal stem cells results in better prognosis in a rat model of myocardial infarction. Eur. J. Heart Fail. 2009, 11(11):1023-1030.
184. Meyerrose T.E., Roberts M., Ohlemiller K.K., Vogler C.A., Wirthlin L., Nolta J.A., Sands M.S. Lentiviral-transduced human mesenchymal stem cells persistently express therapeutic levels of enzyme in a xenotransplantation model of human disease. Stem Cells 2008, 26(7):1713-1722.
185. Wang F., Dennis J.E., Awadallah A., Solchaga L.A., Molter J., Kuang Y., Salem N., Lin Y., Tian H., Kolthammer J.A., Kim Y., Love Z.B., Gerson S.L., Lee Z. Transcriptional profiling of human mesenchymal stem cells transduced with reporter genes for imaging. Physiol. Genomics 2009, 37(1):23-34.
186. Xiang J., Tang J., Song C., Yang Z., Hirst D.G., Zheng Q.J., Li G. Mesenchymal stem cells as a gene therapy carrier for treatment of fibrosarcoma. Cytotherapy 2009, 11(5):516-526.
187. Zhang X.Y., La Russa V.F., Reiser J. Transduction of bone-marrow-derived mesenchymal stem cells by using lentivirus vectors pseudotyped with modified RD114 envelope glycoproteins. J. Virol. 2004, 78(3):1219-1229.
188. Zhang X.Y., La Russa V.F., Bao L., Kolls J., Schwarzenberger P., Reiser J. Lentiviral vectors for sustained transgene expression in human bone marrow-derived stromal cells. Mol. Ther. 2002, 5(5 Pt 1):555-565.
189. Kumar S., Mahendra G., Nagy T.R., Ponnazhagan S. Osteogenic differentiation of recombinant adeno-associated virus 2-transduced murine mesenchymal stem cells and development of an immunocompetent mouse model for ex vivo osteoporosis gene therapy. Hum. Gene Ther. 2004, 15(12):1197-1206.
190. Stender S., Murphy M., O'Brien T., Stengaard C., Ulrich-Vinther M., Soballe K., Barry F. Adeno-associated viral vector transduction of human mesenchymal stem cells. Eur. Cell Mater. 2007, 13:93-99. discussion 99.
191. Deuse T., Peter C., Fedak P.W., Doyle T., Reichenspurner H., Zimmermann W.H., Eschenhagen T., Stein W., Wu J.C., Robbins R.C., Schrepfer S. Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation 2009, 120(11 Suppl):S247-S254.
192. Guo Y.H., He J.G., Wu J.L., Yang L., Zhang D.S., Tan X.Y., Qi R.D. Hepatocyte growth factor and granulocyte colony-stimulating factor form a combined neovasculogenic therapy for ischemic cardiomyopathy. Cytotherapy 2008, 10(8):857-867.
193. Liu X.H., Bai C.G., Xu Z.Y., Huang S.D., Yuan Y., Gong D.J., Zhang J.R. Therapeutic potential of angiogenin modified mesenchymal stem cells: angiogenin improves mesenchymal stem cells survival under hypoxia and enhances vasculogenesis in myocardial infarction. Microvasc. Res. 2008, 76(1):23-30.
194. Tang J., Wang J., Yang J., Kong X., Zheng F., Guo L., Zhang L., Huang Y. Mesenchymal stem cells over-expressing SDF-1 promote angiogenesis and improve heart function in experimental myocardial infarction in rats. Eur. J. Cardiothorac. Surg. 2009, 36(4):644-650.
195. Wang Y., Feng C., Xue J., Sun A., Li J., Wu J. Adenovirus-mediated hypoxia-inducible factor 1alpha double-mutant promotes differentiation of bone marrow stem cells to cardiomyocytes. J. Physiol. Sci. 2009, 59(6):413-420.
196. Wang Y., Sun A., Xue J., Feng C., Li J., Wu J. Bone marrow derived stromal cells modified by adenovirus-mediated HIF-1alpha double mutant protect cardiac myocytes against CoCl2-induced apoptosis. Toxicol. In Vitro 2009, 23(6):1069-1075.
197. Lu Z., Hu X., Zhu C., Wang D., Zheng X., Liu Q. Overexpression of CNTF in Mesenchymal Stem Cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice. J. Neuroimmunol. 2009, 206(1-2):58-69.
198. Lu Z.Q., Hu X.Q., Zhu C.S., Zheng X.P., Wan D.J., Liu R.Y., Huang B.J., Huang W.L. Bone marrow stromal cells transfected with ciliary neurotrophic factor gene ameliorates the symptoms and inflammation in C57BL/6 mice with experimental allergic encephalomyelitis. Nan Fang Yi Ke Da Xue Xue Bao 2009, 29(12):2355-2361.
199. Zhao M.Z., Nonoguchi N., Ikeda N., Watanabe T., Furutama D., Miyazawa D., Funakoshi H., Kajimoto Y., Nakamura T., Dezawa M., Shibata M.A., Otsuki Y., Coffin R.S., Liu W.D., Kuroiwa T., Miyatake S. Novel therapeutic strategy for stroke in rats by bone marrow stromal cells and ex vivo HGF gene transfer with HSV-1 vector. J. Cereb. Blood Flow Metab. 2006, 26(9):1176-1188.
200. Aquino J.B., Bolontrade M.F., Garcia M.G., Podhajcer O.L., Mazzolini G. Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. Gene Ther. 2010, 17(6):692-708.
201. Doering C.B. Retroviral modification of mesenchymal stem cells for gene therapy of hemophilia. Methods Mol. Biol. 2008, 433:203-212.
202. Pipe S.W., High K.A., Ohashi K., Ural A.U., Lillicrap D. Progress in the molecular biology of inherited bleeding disorders. Haemophilia 2008, 14(Suppl 3):130-137.
203. Van Damme A., Chuah M.K., Dell'accio F., De Bari C., Luyten F., Collen D., VandenDriessche T. Bone marrow mesenchymal cells for haemophilia A gene therapy using retroviral vectors with modified long-terminal repeats. Haemophilia 2003, 9(1):94-103.
204. Bartholomew A., Patil S., Mackay A., Nelson M., Buyaner D., Hardy W., Mosca J., Sturgeon C., Siatskas M., Mahmud N., Ferrer K., Deans R., Moseley A., Hoffman R., Devine S.M. Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum. Gene Ther. 2001, 12(12):1527-1541.
205. Devine S.M., Bartholomew A.M., Mahmud N., Nelson M., Patil S., Hardy W., Sturgeon C., Hewett T., Chung T., Stock W., Sher D., Weissman S., Ferrer K., Mosca J., Deans R., Moseley A., Hoffman R. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp. Hematol. 2001, 29(2):244-255.
206. Le Blanc K., Ringden O. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 2005, 11(5):321-334.
207. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 2003, 57(1):11-20.
208. Puissant B., Barreau C., Bourin P., Clavel C., Corre J., Bousquet C., Taureau C., Cousin B., Abbal M., Laharrague P., Penicaud L., Casteilla L., Blancher A. Immunomodulatory effect of human adipose tissue-derived adult stem cells: comparison with bone marrow mesenchymal stem cells. Br. J. Haematol. 2005, 129(1):118-129.
209. Batten P., Sarathchandra P., Antoniw J.W., Tay S.S., Lowdell M.W., Taylor P.M., Yacoub M.H. Human mesenchymal stem cells induce T cell anergy and downregulate T cell allo-responses via the TH2 pathway: relevance to tissue engineering human heart valves. Tissue Eng. 2006, 12(8):2263-2273.
210. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 2002, 99(10):3838-3843.
211. Groh M.E., Maitra B., Szekely E., Koc O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 2005, 33(8):928-934.
212. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101(9):3722-3729.
213. Jones S., Horwood N., Cope A., Dazzi F. The antiproliferative effect of mesenchymal stem cells is a fundamental property shared by all stromal cells. J. Immunol. 2007, 179(5):2824-2831.
214. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., Deans R.J., McIntosh K.R. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed. Sci. 2005, 12(1):47-57.
215. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 2003, 75(3):389-397.
216. Djouad F., Charbonnier L.M., Bouffi C., Louis-Plence P., Bony C., Apparailly F., Cantos C., Jorgensen C., Noel D. Mesenchymal stem cells inhibit the differentiation of dendritic cells through an interleukin-6-dependent mechanism. Stem Cells 2007, 25(8):2025-2032.
217. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005, 105(10):4120-4126.
218. Nauta A.J., Kruisselbrink A.B., Lurvink E., Willemze R., Fibbe W.E. Mesenchymal stem cells inhibit generation and function of both CD34+-derived and monocyte-derived dendritic cells. J. Immunol. 2006, 177(4):2080-2087.
219. Zhang W., Ge W., Li C., You S., Liao L., Han Q., Deng W., Zhao R.C. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 2004, 13(3):263-271.
220. Corcione A., Benvenuto F., Ferretti E., Giunti D., Cappiello V., Cazzanti F., Risso M., Gualandi F., Mancardi G.L., Pistoia V., Uccelli A. Human mesenchymal stem cells modulate B-cell functions. Blood 2006, 107(1):367-372.
221. Aggarwal S., Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 2005, 105(4):1815-1822.
222. Maccario R., Podesta M., Moretta A., Cometa A., Comoli P., Montagna D., Daudt L., Ibatici A., Piaggio G., Pozzi S., Frassoni F., Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005, 90(4):516-525.
223. Prevosto C., Zancolli M., Canevali P., Zocchi M.R., Poggi A. Generation of CD4+ or CD8+ regulatory T cells upon mesenchymal stem cell-lymphocyte interaction. Haematologica 2007, 92(7):881-888.
224. Sato K., Ozaki K., Oh I., Meguro A., Hatanaka K., Nagai T., Muroi K., Ozawa K. Nitric oxide plays a critical role in suppression of T-cell proliferation by mesenchymal stem cells. Blood 2007, 109(1):228-234.
225. Nasef A., Chapel A., Mazurier C., Bouchet S., Lopez M., Mathieu N., Sensebe L., Zhang Y., Gorin N.C., Thierry D., Fouillard L. Identification of IL-10 and TGF-beta transcripts involved in the inhibition of T-lymphocyte proliferation during cell contact with human mesenchymal stem cells. Gene Expr. 2007, 13(4-5):217-226.
226. Nasef A., Mathieu N., Chapel A., Frick J., Francois S., Mazurier C., Boutarfa A., Bouchet S., Gorin N.C., Thierry D., Fouillard L. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007, 84(2):231-237.
227. Hainz U., Jurgens B., Heitger A. The role of indoleamine 2, 3-dioxygenase in transplantation. Transpl. Int. 2007, 20(2):118-127.
228. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2, 3-dioxygenase-mediated tryptophan degradation. Blood 2004, 103(12):4619-4621.
229. Crop M.J., Baan C.C., Korevaar S.S., Ijzermans J.N., Alwayn I.P., Weimar W., Hoogduijn M.J. Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009, 87(6):896-906.
230. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002, 30(1):42-48.
231. Ge W., Jiang J., Baroja M.L., Arp J., Zassoko R., Liu W., Bartholomew A., Garcia B., Wang H. Infusion of mesenchymal stem cells and rapamycin synergize to attenuate alloimmune responses and promote cardiac allograft tolerance. Am. J. Transplant. 2009, 9(8):1760-1772.
232. Wan C.D., Cheng R., Wang H.B., Liu T. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobiliary Pancreat. Dis. Int. 2008, 7(1):29-33.
233. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., Gerson S.L., Laughlin M.J., Loberiza F.R., Moseley A.B., Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 2005, 11(5):389-398.
234. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004, 363(9419):1439-1441.
235. Ball L.M., Bernardo M.E., Roelofs H., Lankester A., Cometa A., Egeler R.M., Locatelli F., Fibbe W.E. Cotransplantation of ex vivo expanded mesenchymal stem cells accelerates lymphocyte recovery and may reduce the risk of graft failure in haploidentical hematopoietic stem-cell transplantation. Blood 2007, 110(7):2764-2767.
236. Ringden O., Uzunel M., Rasmusson I., Remberger M., Sundberg B., Lonnies H., Marschall H.U., Dlugosz A., Szakos A., Hassan Z., Omazic B., Aschan J., Barkholt L., Le Blanc K. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 2006, 81(10):1390-1397.
237. Augello A., Tasso R., Negrini S.M., Cancedda R., Pennesi G. Cell therapy using allogeneic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheum. 2007, 56(4):1175-1186.
238. Park H.K., Cho K.S., Park H.Y., Shin D.H., Kim Y.K., Jung J.S., Park S.K., Roh H.J. Adipose-derived stromal cells inhibit allergic airway inflammation in mice. Stem Cells Dev. March 17 2010, [epub ahead of print].
239. Weiss D.J., Kolls J.K., Ortiz L.A., Panoskaltsis-Mortari A., Prockop D.J. Stem cells and cell therapies in lung biology and lung diseases. Proc. Am. Thorac. Soc. 2008, 5(5):637-667.
240. Nemeth K., Keane-Myers A., Brown J.M., Metcalfe D.D., Gorham J.D., Bundoc V.G., Hodges M.G., Jelinek I., Madala S., Karpati S., Mezey E. Bone marrow stromal cells use TGF-beta to suppress allergic responses in a mouse model of ragweed-induced asthma. Proc. Natl Acad. Sci. USA 2010, 107(12):5652-5657.
241. Cho K.S., Park H.K., Park H.Y., Jung J.S., Jeon S.G., Kim Y.K., Roh H.J. IFATS collection: immunomodulatory effects of adipose tissue-derived stem cells in an allergic rhinitis mouse model. Stem Cells 2009, 27(1):259-265.
242. Iyer S.S., Co C., Rojas M. Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med. 2009, 51(1):5-16.
243. Studeny M., Marini F.C., Champlin R.E., Zompetta C., Fidler I.J., Andreeff M. Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors. Cancer Res. 2002, 62(13):3603-3608.
244. Studeny M., Marini F.C., Dembinski J.L., Zompetta C., Cabreira-Hansen M., Bekele B.N., Champlin R.E., Andreeff M. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl Cancer Inst. 2004, 96(21):1593-1603.
245. Aboody K.S., Najbauer J., Danks M.K. Stem and progenitor cell-mediated tumor selective gene therapy. Gene Ther. 2008, 15(10):739-752.
246. Nakamura K., Ito Y., Kawano Y., Kurozumi K., Kobune M., Tsuda H., Bizen A., Honmou O., Niitsu Y., Hamada H. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 2004, 11(14):1155-1164.
247. Grisendi G., Bussolari R., Cafarelli L., Petak I., Rasini V., Veronesi E., De Santis G., Spano C., Tagliazzucchi M., Barti-Juhasz H., Scarabelli L., Bambi F., Frassoldati A., Rossi G., Casali C., Morandi U., Horwitz E.M., Paolucci P., Conte P., Dominici M. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010, 70(9):3718-3729.
248. Loebinger M.R., Eddaoudi A., Davies D., Janes S.M. Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res. 2009, 69(10):4134-4142.
249. Menon L.G., Kelly K., Yang H.W., Kim S.K., Black P.M., Carroll R.S. Human bone marrow-derived mesenchymal stromal cells expressing S-TRAIL as a cellular delivery vehicle for human glioma therapy. Stem Cells 2009, 27(9):2320-2330.
250. Sasportas L.S., Kasmieh R., Wakimoto H., Hingtgen S., van de Water J.A., Mohapatra G., Figueiredo J.L., Martuza R.L., Weissleder R., Shah K. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc. Natl Acad. Sci. USA 2009, 106(12):4822-4827.
251. Hamada H., Kobune M., Nakamura K., Kawano Y., Kato K., Honmou O., Houkin K., Matsunaga T., Niitsu Y. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 2005, 96(3):149-156.
252. Nakamizo A., Marini F., Amano T., Khan A., Studeny M., Gumin J., Chen J., Hentschel S., Vecil G., Dembinski J., Andreeff M., Lang F.F. Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res. 2005, 65(8):3307-3318.